Brain Tumor Clinical Trial
Official title:
Comparison of the Effects of Vecuronium and Cisatracurium on Electrophysiologic Monitoring During Neurosurgery
Verified date | December 2013 |
Source | Samsung Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | South Korea: Institutional Review Board |
Study type | Interventional |
Recently intraoperative motor evoked potential monitoring (MEP) is widely used to reduce
neural damage during neurosurgery.
As neuromuscular blockade(NMB) during MEP monitoring decreases the amplitude of MEP, partial
NMB is usually maintained during general anesthesia. Continuous infusion of NMB agent is
preferred than bolus infusion during MEP monitoring. There are a lot of NMB agents in
clinical use. But there have been no reports about the effect of changing NMB agent on
efficacy of MEP monitoring.
Therefore, the investigators performed a randomized controlled trial to evaluate the effect
of changing NMB agent on the variability of MEP amplitude during neurosurgery.
Status | Completed |
Enrollment | 74 |
Est. completion date | March 2013 |
Est. primary completion date | March 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Adult patients undergoing neurosurgery with intraoperative motor evoked potential monitoring Exclusion Criteria: - Patients who can not undergo motor evoked potential monitoring due to central or peripheral neuromuscular disease (e.g. Cerebral palsy, Myasthenia gravis, Acute spinal injury, neurologic shock) - Patients with hepatic or renal disease with altered metabolism of vecuronium - Patients with medication which influence the metabolism of vecuronium (e.g. calcium channel blocker, aminoglycoside antibiotics, Lithium, MgSO4) |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Samsung Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Samsung Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 15 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 30 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 45 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 60 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 75 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 90 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 105 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 120 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 135 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 150 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 165 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 180 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 195 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 210 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 225 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 240 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 255 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 270 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 285 min after anesthetic induction | No |
Primary | MEP amplitude | intraoperative motor evoked potential monitoring amplitude | 300 min after anesthetic induction | No |
Secondary | Coefficient of variation (CV) of MEP amplitude | Coefficient of variation (CV) of intraoperative motor evoked potential monitoring amplitude | at the end of the surgery (5H after the start of surgery) | No |
Secondary | Average of MEP amplitudes | Average of all measured MEP amplitudes in a subject | at the end of the surgery (5H after the start of surgery) | No |
Secondary | The frequency of adjusting the infusion dose of muscle relaxant | The frequency of adjusting the infusion dose of muscle relaxant | at the end of the surgery (5H after the start of surgery) | No |
Secondary | Average of Latency of MEP amplitude | Average of Latency of MEP amplitude | at the end of the surgery (5H after the start of surgery) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05023434 -
A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
|
||
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Completed |
NCT02768389 -
Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
|
Early Phase 1 | |
Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT03286335 -
Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy
|
N/A | |
Recruiting |
NCT05968053 -
Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
|
||
Recruiting |
NCT05358340 -
Dual Perfusion Imaging for Characterizing Vascular Architecture of Brain Lesions
|
N/A | |
Recruiting |
NCT03276676 -
[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors
|
Phase 2 | |
Completed |
NCT02851355 -
Follow-up Survey of Patients Who Were Treated for Medulloblastoma or Primitive Neuroectodermal Tumors of the Central Nervous in Norway
|
||
Completed |
NCT02713087 -
Vasopressor Effects in Anesthetized Patients
|
Phase 4 | |
Completed |
NCT02409121 -
A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers
|
N/A | |
Completed |
NCT02558569 -
The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block
|
Phase 4 | |
Withdrawn |
NCT02165995 -
Use of Navigated Transcranial Magnetic Stimulation (nTMS) in Generated Motor and Language Mapping to Evaluate Brain Recovery Following Surgery
|
N/A | |
Terminated |
NCT02674945 -
Understanding and Improving Quality of Life Through a Wireless Activity Tracker: Observational Phase
|
||
Withdrawn |
NCT01202539 -
Real-time Assessment of Frameless Intrafraction Motion
|
||
Completed |
NCT01171469 -
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
|
Phase 1 | |
Terminated |
NCT01044966 -
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT00760409 -
Differentiating Recurrent Brain Tumor Versus Radiation Injury Using MRI
|
N/A | |
Completed |
NCT00503204 -
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
|
Phase 1 |